First, there is no evidence that any of the C-19 vaccines proven to be efficacious in a clinical research setting will prevent the virus from successfully exploiting its evolutionary capacity when challenged by widespread immune pressure exerted by the population on the very protein that these vaccines are directed at (i.e., at spike [S] protein).